Trial Profile
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms BONSAI; Meeturo 2
- 06 Dec 2022 Results (n=4) assessing outcomes of patients enrolled in the BONSAI trial that received nivolumab as second-line treatment published in the Tumori
- 13 Sep 2022 Results of exploratory endpoints (n=18) assessing baseline mCDC transcriptome is associated with outcome and/or predictive immune signatures, presented at the 47th European Society for Medical Oncology Congress.
- 07 Jun 2022 Results of a molecular analyses of metastatic collecting ducts renal cell carcinoma presented at the 58th Annual Meeting of the American Society of Clinical Oncology